Phototoxicity and photocarcinogenesis associated with voriconazole

Medecine et Maladies Infectieuses

Volumn 41, Issue 12, 2011, Pages 639-645

  Epaulard, O ^a,b   Leccia, M T ^a,b   Blanche, S ^b,c   Chosidow, O ^b,d,e   Mamzer Bruneel, M F ^b,c   Ravaud, P ^b,f   Thiebaut, A ^a,b   Villier, C ^b,g   Lortholary, O ^b,c,h  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b Bureau scientifique de l'étude Voripeau   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^f HÔTEL DIEU   (France)

^g Centre Régional de Pharmacovigilance   (France)

^h CNRS   (France)

Author keywords

Carcinogenesis; Carcinoma; Immunodeficiency; Phototoxicity; Skin; Voriconazole

Indexed keywords

AMIODARONE; CYCLINE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLITE; FLUCONAZOLE; ITRACONAZOLE; KETOPROFEN; PHENOTHIAZINE DERIVATIVE; POSACONAZOLE; PYRROLE DERIVATIVE; QUININE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOIC ACID; RETINOID; RETINOID DERIVATIVE; VORICONAZOLE;

ACUTE LEUKEMIA; ALOPECIA; AREA UNDER THE CURVE; BULLOUS SKIN DISEASE; CANCER PREVENTION; CANCER RISK; CANDIDEMIA; CHEILITIS; DELAYED DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIDERMOLYSIS; ERYTHEMA; HUMAN; IMMUNE DEFICIENCY; INVASIVE ASPERGILLOSIS; LIVER DISEASE; MELANOMA; MYELODYSPLASTIC SYNDROME; PHOTOALLERGY; PHOTOSENSITIVITY; PHOTOTOXICITY; PRESCRIPTION; PROGNOSIS; PRURITUS; PSORIASIS; RADIATION ABSORPTION; RADIATION CARCINOGENESIS; REVIEW; SKIN BIOPSY; SKIN CANCER; SKIN CARCINOMA; SKIN DEFECT; SKIN DISEASE; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; SUNLIGHT PROTECTION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

ANTIFUNGAL AGENTS; BIOTRANSFORMATION; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COCARCINOGENESIS; COMORBIDITY; DERMATITIS, PHOTOTOXIC; DRUG INTERACTIONS; HUMANS; IMMUNOCOMPROMISED HOST; MELANOMA; MYCOSES; NEOPLASMS, RADIATION-INDUCED; PHOTOCHEMISTRY; POSTOPERATIVE COMPLICATIONS; PYRIMIDINES; RETINOIDS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SUNLIGHT; TRANSPLANTATION; TRIAZOLES;

EID: 83355169572     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2011.09.016     Document Type: Review

References (66)

1. Nivoix Y., Velten M., Letscher-Bru V., et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008, 47:1176-1184.
2. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New Engl J Med 2002, 347:408-415.
3. Kullberg B.J., Sobel J.D., Ruhnke M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005, 366:1435-1442.
4. Lortholary O., Obenga G., Biswas P., et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010, 54:4446-4450.
5. Lortholary O., Gangneux J.P., Sitbon K., et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clin Microbiol Infect 2011, (sous presse).
6. Troke P., Aguirrebengoa K., Arteaga C., et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008, 52:1743-1750.
7. Ally R., Schurmann D., Kreisel W., et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001, 33:1447-1454.
8. Perfect J.R., Marr K.A., Walsh T.J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36:1122-1131.
9. Denning D.W., Ribaud P., Milpied N., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34:563-571.
10. Hilliard T., Edwards S., Buchdahl R., et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 2005, 4:215-220.
11. Purkins L., Wood N., Ghahramani P., Greenhalgh K., Allen M.J., Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002, 46:2546-2553.
12. Purkins L., Wood N., Greenhalgh K., Allen M.J., Oliver S.D. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. British J Clin Pharmacol 2003, 56(Suppl. 1):10-16.
13. Queiroz-Telles F., Goldani L.Z., Schlamm H.T., Goodrich J.M., Espinel-Ingroff A., Shikanai-Yasuda M.A. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis 2007, 45:1462-1469.
14. Vehreschild J.J., Bohme A., Buchheidt D., et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007, 55:445-449.
15. Vehreschild J.J., Bohme A., Reichert D., et al. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. Int J Hematol 2008, 87:126-131.
16. Walsh T.J., Lutsar I., Driscoll T., et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Ped Infect Dis J 2002, 21:240-248.
17. Wingard J.R., Carter S.L., Walsh T.J., et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010, 116:5111-5118.
18. Cordonnier C., Rovira M., Maertens J., et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010, 95:1762-1768.
19. Sambatakou H., Dupont B., Lode H., Denning D.W. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 2006, 119. 527.e17-24.
20. Mattiuzzi G.N., Cortes J., Alvarado G., et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer 2011, 19:19-26.
21. Torres A., Serrano J., Rojas R., et al. Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia. Eur J Haematol 2010, 84:271-273.
22. Martin T., Sharma M., Damon L., et al. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation. Transplant Infect Dis 2010, 12:45-50.
23. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. New Engl J Med 2002, 346:225-234.
24. Marks D.I., Kibbler C., Pagliuca A., et al. Voriconazole vs. itraconazole for primary prophylaxis of invasive fungal infection in allogeneic hematopoietic cell transplant recipients. ICAAC 2009, [abstract M-1249a].
25. Ferguson J. fluoroquinolones sensitization: a review of clinical and laboratories studies. Photochem Photobiol 1995, 62:954-958.
26. Auffret N., Janssen F., Chevalier P., Guillemain R., Amrein C., Le Beller C. Photosensibilisation au voriconazole: 7 cas. Ann Dermatol Venereol 2006, 133:330-332.
27. Brunel A.S., Fraisse T., Lechiche C., Pinzani V., Mauboussin J.M., Sotto A. Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy. AIDS 2008, 22:905-906.
28. Cheng M.P., Paquette K., Lands L.C., Ovetchkine P., Theoret Y., Quach C. Voriconazole inhibition of vitamin A metabolism: are adverse events increased in cystic fibrosis patients?. Ped Pulmonol 2010, 45:661-666.
29. Cortez K.J., Walsh T.J., Bennett J.E. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 2003, 36:1619-1622.
30. Cowen E.W., Nguyen J.C., Miller D.D., et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010, 62:31-37.
31. Denning D.W., Griffiths C.E. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 2001, 26:648-653.
32. Dolan C.K., Hall M.A., Blazes D.L., Norwood C.W. Pseudoporphyria as a result of voriconazole use: a cases report. Int J Dermatol 2004, 43:768-771.
33. Epaulard O., Saint-Raymond C., Villier C., et al. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients. Clin Microbiol Inf 2010, 16:1362-1364.
34. Frick M.A., Soler-Palacin P., Martin Nalda A., Guarner M.E., Nadal C.F. Photosensitivity in immunocompromised patients receiving long-term therapy with oral voriconazole. Ped Infect Dis J 2010, 29:480-481.
35. Frisch S., Askari S.K., Beaty S.R., Burkemper C.N. X-linked chronic granulomatous disease with voriconazole-induced photosensitivity/photoaging reaction. J Drugs Dermatol 2010, 9:562-564.
36. Hickman G., Duval A., Picard C., Petit A. Porphyrie cutanée tardive révélée par le voriconazole. Ann Dermatol Venereol 2010, 137:36-39.
37. Ibrahim S.F., Singer J.P., Arron S.T. Catastrophic squamous cell carcinoma in lung transplant patients treated with voriconazole. Dermatol Surg 2010, 36:1752-1755.
38. Kwong W.T., Hsu S. Pseudoporphyria associated with voriconazole. J Drugs Dermatol 2007, 6:1042-1044.
39. Malani A.N., Aronoff D.M. Voriconazole-induced photosensitivity. Clin Med Res 2008, 6:83-85.
40. McCarthy K.L., Playford E.G., Looke D.F., Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007, 44:e55-e56.
41. Miller D.D., Cowen E.W., Nguyen J.C., McCalmont T.H., Fox L.P. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010, 146:300-304.
42. Morice C., Acher A., Soufir N., et al. Multifocal aggressive squamous cell carcinomas induced by prolonged voriconazole therapy: a cases report. Case Rep Med 2010, 2010:351084.
43. Patel A.R., Turner M.L., Baird K., et al. Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2009, 15:370-376.
44. Racette A.J., Roenigk H.H., Hansen R., Mendelson D., Park A. Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl. J Am Acad Dermatol 2005, 52:S81-S85.
45. Riahi R.R., Cohen P.R. Voriconazole-associated phototoxicity. Dermatol Online J 2011, 17:15.
46. Rubenstein M., Levy M.L., Metry D. Voriconazole-induced retinoid-like photosensitivity in children. Ped Dermatol 2004, 21:675-678.
47. Serra Soler G., Delgado Sanchez O., Esteban Marcos E., Martinez-Lopez I., Femenias Sureda M. Voriconazole-associated phototoxicity. Farmac Hospit 2006, 30:386-387.
48. Sharp M.T., Horn T.D. Pseudoporphyria induced by voriconazole. J Am Acad Dermatol 2005, 53:341-345.
49. Tolland J.P., McKeown P.P., Corbett J.R. Voriconazole-induced pseudoporphyria. Photodermatol Photoimmunol Photomed 2007, 23:29-31.
50. Vanacker A., Fabre G., Van Dorpe J., Peetermans W.E., Maes B. Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient. Am J Transplant 2008, 8:877-880.
51. Vandecasteele S.J., Van Wijngaerden E., Peetermans W.E. Two cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazole. Eur J Clin Microbiol Inf Dis 2004, 23:656-657.
52. Vohringer S., Schrum J., Ott H., Hoger P.H. Severe phototoxicity associated with long-term voriconazole treatment. J Germ Soc Dermatol 2011, 9:274-276.
53. Eiden C., Peyriere H., Cociglio M., et al. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007, 41:755-763.
54. Curigliano G., Formica V., De Pas T., et al. Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. Ann Oncol 2006, 17:1174-1175.
55. Huang D.B., Wu J.J., Lahart C.J. Toxic epidermal necrolysis as a complication of treatment with voriconazole. South Med J 2004, 97:1116-1117.
56. Conlon J.D., Dauenhauer M., Tonkovic-Capin V., et al. Voriconazole-induced blistering in the setting of graft versus host disease: a report of 2 patients. J Am Acad Dermatol 2008, 58:484-487.
57. Lankerani L., Baron E. Photosensitivity to exogenous agents. J Cutan Med Surg 2004, 8:424-431.
58. Moore D.E. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002, 25:345-372.
59. Pappas P.G., Kauffman C.A., Perfect J., et al. Alopecia associated with fluconazole therapy. Ann Intern Med 1995, 123:354-357.
60. Theuretzbacher U., Ihle F., Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokin 2006, 45:649-663.
61. Scholz I., Oberwittler H., Riedel K.D., et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009, 68:906-915.
62. Murayama N., Imai N., Nakane T., Shimizu M., Yamazaki H. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol 2007, 73:2020-2026.
63. Schwartz E.L., Hallam S., Gallagher R.E., Wiernik P.H. Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. Biochem Pharmacol 1995, 50:923-928.
64. Feist A.A., Osborne S.L., Thistlethwaite P.A., Madani M., Reed S., Yung G. Voriconazole use increases the incidence of skin cancer in lung transplant recipients. J Heart Lung Transplant 2009, 28:S242.
65. Vadnerkar A., Nguyen M.H., Mitsani D., et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010, 29:1240-1244.
66. Klecak G., Urbach F., Urwyler H. Fluoroquinolone antibacterials enhance UVA-induced skin tumors. J Photochem Photobiol 1997, 37:174-181.